Questions for the scientific and business model aficionados on this Board. I'm not certain any of them can be answered, but even taking a stab at them would be helpful.
(1) Am I correct in assuming that, based upon the "planned" second half of the year meeting with the FDA regarding Cotara, that the earliest possible commercialization of the product would not be until 2013/2014 at the earliest?
(2) Given the status of where Bavituximab is at the moment, what would be a realistic projection for a product ready for commercialization?
(3) Is it your impression that PPHM is still seriously interested in biosimilars? Correct me if I'm wrong, but I don't remember hearing much about them lately in terms of PPHM's future plans. Was this just a throwaway line during a particular quarterly report?
(4) King said at the end of the conference yesterday, We are gearing up for what we expect to be a robust flow of clinical data reports throughout the rest of this year and into next year. This represents significant opportunities for potential value creation over the coming year...." Realistically, what is the meaning of the phrase, "significant opportunities for potential value creation"?
I know there are unknowns such as partnering and regional licensing, etc. But these unknowns have been speculated on for the 11 years that I've owned this company; at this point, I see no evidence that would indicate that this management has such plans.
These questions I ask because I was in my late 40s when I invested in this company; I'm now 60. I've lost a lot of $ in PPHM by holding and not selling during this time. Given the present economic environment and my age, I'm considering putting the money to work elsewhere. I thought originally that this company would provide a fine nest egg for my retirement. I think it still will for many here, but I'm not certain I've the time to find out.
I read RRdog's fine post the other day; he remains optimistic despite everything (as I do about the potential science). But he implies that they've made $ trading this company. Perhaps that should be considered by some of us for whom time has become a consideration. Volgoat and Swingtrader are fine technicians and could be valuable community contributors alerting us to any significant technical signals. Trading this security using technical analysis would by no means be foolproof, but it can't be any worse than holding for years and seeing time and money dissipate.
I need to say this: thank you to all on this board who take the time to keep us updated on the science and business implications of press releases. Without this Board, many of us would be lost due to the scarcity of information from management. I think management is doing their best, but I've begun to think that they really might be in over their heads. That doesn't mean that I don't think they'll be ultimately successful; I just don't know if I have the luxury of time to find out.
Thanks for your thoughts ahead of time.
Sean
AI
